Merck Sharp & Dohme Llc

This early-stage study tests a new vaccine called V540D in 72 healthy adults. The vaccine is designed to protect against the same nine HPV types as the current GARDASIL®9 vaccine, plus additional HPV types that can cause cancer. The main goal is to check if the vaccine is safe an…

This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in 60 adults with advanced clear-cell kidney cancer that worsened after at least two prior treatments. The goal is to see if the combination is safe and effective, and to find the best …

This study tests an experimental drug called zilovertamab vedotin in 140 people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and how long that effect lasts. Participants r…

This study tests a new medicine called raludotatug deruxtecan in people with advanced gastrointestinal cancers, including pancreatic, bile duct, colorectal, stomach, and gastroesophageal junction cancers. The drug works like a guided missile, attaching to a protein on cancer cell…

This study looks at adding pembrolizumab (an immunotherapy drug) to standard chemotherapy for children and young adults newly diagnosed with classical Hodgkin lymphoma whose cancer didn't shrink enough after initial chemo. About 340 participants will receive this combination to s…

This study looks at the safety and tolerability of a lower-dose HIV-1 medication (DOR/ISL 100 mg/0.25 mg) taken once daily. It involves 641 adults who were already on a higher dose of the same drug in earlier studies. The main goal is to track side effects and how many people sto…

This study is for people with advanced melanoma that hasn't been treated yet. Researchers are testing whether adding other drugs to the standard treatment pembrolizumab can shrink tumors more effectively. The trial involves about 315 participants and focuses on safety and how wel…

This study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) can prevent muscle-invasive bladder cancer from coming back after surgery. About 230 adults with high-risk bladder cancer will receive either the vaccine plus immunother…

This study is for adults with high cholesterol who have already completed an earlier study of the experimental drug MK-0616 (enlicitide decanoate). The main goal is to check the drug's safety over a longer period by tracking side effects. About 3,000 participants will take the dr…

This study tests whether adding the immunotherapy drug pembrolizumab before and after surgery can help people with advanced head and neck cancer stay cancer-free longer. About 714 participants will receive either pembrolizumab plus standard radiation (with or without chemo) or ra…

This study tests an experimental daily pill, MK-0616, to see if it can prevent major heart problems like heart attacks, strokes, and blocked arteries in people with high risk due to hardening of the arteries and high cholesterol. About 14,550 adults will take either the pill or a…

This study tests whether adding a new drug (belzutifan or quavonlimab) to a standard two-drug therapy helps people with advanced clear cell kidney cancer live longer or keep their cancer from growing. About 1,650 adults who have not had prior treatment for advanced disease will b…

This study tests whether adding new drugs (favezelimab or vibostolimab) to the standard combination of pembrolizumab and enfortumab vedotin can better shrink tumors in people with advanced bladder cancer that has not been treated before. About 390 participants will receive one of…

This early-stage study tests a new drug, MK-2870, alone or with pembrolizumab (and sometimes chemotherapy) in Japanese adults with advanced solid tumors or a type of lung cancer. The main goal is to check safety and find the right dose. About 30 people will take part.

This study compares a new shot form of the immunotherapy drug pembrolizumab (given under the skin) with the standard IV version, both combined with chemotherapy, as a first treatment for adults with metastatic non-small cell lung cancer. The main goal is to see if the shot delive…

This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in Chinese patients with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety, how the body processes the drugs, and initial sig…

This study tests whether adding belzutifan (a pill) to standard immunotherapy (pembrolizumab) can better prevent kidney cancer from returning after surgery to remove the kidney. About 1,800 adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrenc…

This study tests a drug called MK-2140 (zilovertamab vedotin) in people with certain B-cell blood cancers that have come back or not responded to other treatments. About 189 adults with mantle cell lymphoma, Richter's transformation lymphoma, follicular lymphoma, or chronic lymph…

This study tests a new drug called belzutifan against an older drug, everolimus, in 755 people with advanced kidney cancer that got worse after prior treatments. The goal is to see if belzutifan can slow cancer growth or help people live longer. Participants must have a specific …

This study tests a new way to give the cancer drug pembrolizumab—as a shot under the skin—to adults with Hodgkin lymphoma or primary mediastinal B-cell lymphoma that has come back or not responded to treatment. The main goals are to see how the drug moves in the body and how many…

This study compares a new oral targeted therapy, nemtabrutinib, against standard chemoimmunotherapy in 300 people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a specific genetic change (TP53 mutation). The main g…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with this type of ovarian cance…

This study compares a new shot form of the immunotherapy drug pembrolizumab (given under the skin) with the standard IV version, both combined with chemotherapy, as a first treatment for adults in Japan with metastatic non-small cell lung cancer. The goal is to see if the shot wo…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with advanced esophageal cancer live longer without the disease getting worse. About 700 participants who cannot have surgery will receive either pembrolizumab …

This study tests whether a shot under the skin (subcutaneous) of the immunotherapy drug pembrolizumab works as well as the standard IV infusion for people with advanced non-small cell lung cancer that has spread. About 67 participants will receive either the shot or the IV, and r…

This study tests whether adding the drugs pembrolizumab and olaparib to standard chemoradiation helps people with stage III non-small cell lung cancer that cannot be surgically removed. About 870 participants will receive either pembrolizumab with or without olaparib after chemor…

This study tests whether adding sacituzumab govitecan to the immunotherapy drug pembrolizumab helps people with a specific type of advanced lung cancer live longer or keep their cancer from growing, compared to pembrolizumab alone. About 614 adults whose tumors have high levels o…

This study looked at whether giving the immunotherapy drug pembrolizumab (Keytruda) after surgery for high-risk stage III melanoma helps keep the cancer from returning. About 1,000 participants were randomly assigned to receive either pembrolizumab or a placebo (inactive treatmen…

This study tests a new drug, MK-2870, against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to targeted pills. About 520 participants will be randomly assigned to receive either…

This study tests a new combination of drugs (MK-2870 plus enfortumab vedotin, with or without pembrolizumab) in people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 38 adults will take part in two phases: fir…

This early-stage study looks at whether a shot under the skin (subcutaneous injection) of pembrolizumab works as well as the standard IV version for people with advanced solid tumors. About 72 adults will receive different doses to measure how much drug gets into the blood and to…

This study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…

This study tests a new drug called MK-2870 against the doctor's choice of standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread or cannot be removed. About 450 participants who have already tried at least two prior t…

This study tests a new drug combination (pembrolizumab plus berahyaluronidase alfa) given as a shot under the skin for Japanese patients with advanced squamous cell skin cancer that has spread or cannot be removed by surgery. The main goal is to see if the treatment shrinks tumor…

This early-stage study tests an experimental drug called MK-6837, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks …

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can help prevent kidney cancer from returning after surgery. About 272 people with intermediate- to high-risk kidney cancer will receive either the vaccine plus immunothe…

This study tests whether adding two new drugs (belzutifan and lenvatinib, or a pembrolizumab/quavonlimab combo with lenvatinib) to standard treatment can help Chinese patients with advanced clear cell kidney cancer live longer and slow tumor growth. About 249 participants will re…

This early-phase study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers that have returned or not responded to prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. This is not a cure…

This study tests if a new once-weekly pill (ISL+ULO) can keep HIV under control as well as a standard daily pill (BIC/FTC/TAF). About 150 adults with already-suppressed HIV will switch to the weekly pill or stay on their daily regimen. Researchers will check virus levels and side…

This study tests an experimental drug called efinopegdutide in 80 adults with liver scarring (cirrhosis) caused by a type of fatty liver disease (MASH). The goal is to see if the drug can lower liver fat, inflammation, and scarring over about 7 months. Participants will receive e…

This phase 3 study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer getting worse. About 340 participants who have already tried hormone therap…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are not having their bladder removed wil…

This study tests whether adults with HIV who are already undetectable on a three-drug regimen can safely switch to a new two-drug pill (doravirine/islatravir) taken once daily. About 514 participants will be randomly assigned to either switch or stay on their current medication. …

This study compares the immunotherapy drug pembrolizumab to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic marker (dMMR). The goal is to see if pembrolizumab can better delay cancer growth or improve survival. Particip…

This study compares a new drug, MK-2870, to standard chemotherapy for people with endometrial cancer that has already been treated with platinum chemo and immunotherapy. About 710 participants will receive either MK-2870 alone or a doctor-chosen chemo. The goal is to see if MK-28…

This study tests experimental combinations of drugs for people with advanced kidney cancer (clear cell renal cell carcinoma) that has spread and hasn't been treated yet. About 400 participants will receive the drug combinations to see if they are safe and help shrink tumors. The …

This study tests a new once-daily pill (doravirine/islatravir) for people with HIV who have never taken HIV medication before. About 537 participants will receive either the new pill or a standard combination pill to see how well they control the virus and how safe they are. The …

This study tests whether switching to a new once-daily combination pill (Doravirine/Islatravir) is as safe and effective as staying on current HIV medications. About 550 adults with HIV-1 who have undetectable virus levels will take either the new pill or continue their usual tre…

This phase 3 study tests whether a new drug combination (belzutifan + lenvatinib) works better than the current standard drug (cabozantinib) for people with advanced kidney cancer that has gotten worse after prior immunotherapy. About 747 participants will receive either the comb…

This study tests an experimental drug called MK-7240 (tulisokibart) in about 1020 people with moderate to severe ulcerative colitis. The goal is to see if the drug can help patients achieve and maintain remission (fewer symptoms and healed gut lining) compared to a placebo. Parti…

This study looks at the long-term safety of a once-daily pill combining two drugs (Doravirine and Islatravir) for people with HIV-1. It involves 2,000 participants who already took this medication in earlier studies and are continuing it. The main goal is to track serious side ef…

This study was designed to see if adding the experimental drug boserolimab to standard chemotherapy and immunotherapy before surgery could help people with high-risk early-stage triple-negative breast cancer. Researchers planned to check safety and whether the cancer completely d…

This study tests a daily pill called olaparib in people with advanced cancers that have not responded to standard treatments. It is for patients whose tumors have specific gene changes (HRRm or HRD). The goal is to see if the drug can shrink tumors and control the cancer for as l…

This study tests whether adding a personalized mRNA vaccine (V940) to the immunotherapy drug pembrolizumab can prevent melanoma from returning in people with high-risk stage II-IV melanoma. About 1,089 participants who had their melanoma surgically removed will receive either the…

This study tests whether combining two drugs, olaparib and pembrolizumab, can shrink or control advanced solid tumors that have certain DNA repair issues. About 300 adults whose cancer has not responded to standard treatments will receive the drug combination. The goal is to see …

This study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps people with high-risk bladder cancer that hasn't spread into the muscle. About 1,400 participants receive either BCG alone or BCG plus pembrolizumab. The goal is to see if the com…

This study tests whether adding the drug lenvatinib to a standard treatment (pembrolizumab plus chemotherapy) helps people with advanced esophageal cancer live longer. About 864 participants will receive either the new three-drug combo or the standard two-drug combo. The goal is …

This study tests an experimental drug called MK-5475 (frespaciguat) in adults who have both COPD and pulmonary hypertension (high blood pressure in the lungs). The main goal is to see if the drug helps people walk farther in 6 minutes after 24 weeks compared to a placebo. About 1…

This study compares a new drug, MK-2870, to standard chemotherapy (docetaxel or pemetrexed) in 556 adults with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations or others). The goal is to see if MK-2870 can slow cancer growth and help people li…

This study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a painful skin condition. Participants receive either the drug or a placebo to see if it reduces abscesses and inflammation by at least half after 16 weeks. The goal is…

This study looks at the long-term safety of a medicine called sotatercept for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 130 adults who completed a previous study will receive weight-based doses of sotatercept …

This study tests a new combination of two immunotherapy drugs (MK-1308A) against other treatments for people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if the new combo can shrink tumors or slow the disease. About 302 adults with stage IV …

This study is for people with advanced kidney cancer that has gotten worse after initial treatment. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 370 participants will receive experimental treatments, and researchers will monitor side eff…

This study looks at whether people with certain cancers prefer getting their pembrolizumab as a shot under the skin (subcutaneous) instead of through an IV. About 147 adults with lung cancer, kidney cancer, or melanoma will try both methods and report which they like better. The …

This study tests whether adding MK-1167 to standard Alzheimer's medication can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. The main goals are to see if the drug imp…

This study looks at how different tablet versions of the drug enlicitide are absorbed and processed in the bodies of 30 healthy adults. Researchers will measure drug levels in the blood over time and monitor for any side effects. The goal is to find out which tablet form works be…

This study looks at how a common heart medication, diltiazem, changes the amount of the experimental cancer drug nemtabrutinib in the body. About 26 healthy adults will take nemtabrutinib with and without diltiazem, and researchers will measure drug levels in their blood. The goa…

This study involves 60 healthy adults to see if a single tablet containing two medicines (enlicitide and rosuvastatin) works the same as taking them separately. Researchers measure drug levels in the blood over time. The goal is to understand absorption, not to treat any disease.

This early-stage study is testing two different versions of MK-1167, an experimental medicine being developed for Alzheimer's disease, in 16 healthy adults. The main goal is to see how the drug moves through the body and to check its safety before testing it in people with Alzhei…